Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)–low gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS: Patients with locally advanced or metastatic HER2-low (cohort 1, immunohistochemistry 2+/in situ hybridizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Kensei, Bang, Yung-Jue, Iwasa, Satoru, Sugimoto, Naotoshi, Ryu, Min-Hee, Sakai, Daisuke, Chung, Hyun Cheol, Kawakami, Hisato, Yabusaki, Hiroshi, Lee, Jeeyun, Shimoyama, Tatsu, Lee, Keun-Wook, Saito, Kaku, Kawaguchi, Yoshinori, Kamio, Takahiro, Kojima, Akihito, Sugihara, Masahiro, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901967/
https://www.ncbi.nlm.nih.gov/pubmed/36379002
http://dx.doi.org/10.1200/JCO.22.00575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901967/
https://www.ncbi.nlm.nih.gov/pubmed/36379002
http://dx.doi.org/10.1200/JCO.22.00575

Ejemplares similares